Drug Approval | February 05, 2026
Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Inspection included drug device combinations covering our recent filing in nasal sprays domain
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The base Gland business posted ?11,790 million in revenue, up 16% YoY
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
Subscribe To Our Newsletter & Stay Updated
